Li N - Search Results

1

Wang X, Peng W, Zhao Y, Sha J, Li N, Huang S, Wang H. Wang X, et al. Among authors: li n. Front Oncol. 2024 Jun 6;14:1370801. doi: 10.3389/fonc.2024.1370801. eCollection 2024. Front Oncol. 2024. PMID: 38903709 Free PMC article.

2

Efficacy and safety of anti-PD-1 antibody plus chemoradiotherapy in locally advanced esophageal squamous cancer.

Ma J, Yao N, Lu J, Qu W, Cui L, Yuan S, Li N, Tong S, Qin Z, Yao Y. Ma J, et al. Among authors: li n. Front Oncol. 2023 Feb 9;13:1005856. doi: 10.3389/fonc.2023.1005856. eCollection 2023. Front Oncol. 2023. PMID: 36845696 Free PMC article.

3

Identification of the Diagnostic Biomarker VIPR1 in Hepatocellular Carcinoma Based on Machine Learning Algorithm.

Ge S, Xu CR, Li YM, Zhang YL, Li N, Wang FT, Ding L, Niu J. Ge S, et al. Among authors: li ym, li n. J Oncol. 2022 Sep 15;2022:2469592. doi: 10.1155/2022/2469592. eCollection 2022. J Oncol. 2022. PMID: 36157238 Free PMC article.

4

Pan-cancer analysis of kinesin family members with potential implications in prognosis and immunological role in human cancer.

Zhong M, Gong L, Li N, Guan H, Gong K, Zhong Y, Zhu E, Wang X, Jiang S, Li J, Lei Y, Liu Y, Chen J, Zheng Z. Zhong M, et al. Among authors: li j, li n. Front Oncol. 2023 Aug 29;13:1179897. doi: 10.3389/fonc.2023.1179897. eCollection 2023. Front Oncol. 2023. PMID: 37711200 Free PMC article.

5

GASC1-Adapted Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma: A Prospective Clinical Biomarker Trial.

Jia R, Mi Y, Yuan X, Kong D, Li W, Li R, Wang B, Zhu Y, Kong J, Ma Z, Li N, Mi Q, Gao S. Jia R, et al. Among authors: li w, li n, li r. J Oncol. 2020 Jan 30;2020:1607860. doi: 10.1155/2020/1607860. eCollection 2020. J Oncol. 2020. PMID: 32411232 Free PMC article.

6

Circulating the HLA-DR+ T Cell Ratio Is a Prognostic Factor for Recurrence of Patients with Hepatocellular Carcinoma after Curative Surgery.

Gao RQ, Sun JH, Ma YH, Xie YW, Shao GM, Wang C, Tan B, Liu K, Li K, Li N, Hu WY, Cao J. Gao RQ, et al. Among authors: li n, li k. J Oncol. 2023 Feb 23;2023:1875153. doi: 10.1155/2023/1875153. eCollection 2023. J Oncol. 2023. PMID: 36873738 Free PMC article.

7

TIPE1 Inhibits Breast Cancer Proliferation by Downregulating ERK Phosphorylation and Predicts a Favorable Prognosis.

Hu W, Feng CM, Liu LY, Li N, Tian F, Du JX, Zhao Y, Xiang XX, Liu K, Zhao PQ. Hu W, et al. Among authors: li n. Front Oncol. 2019 May 22;9:400. doi: 10.3389/fonc.2019.00400. eCollection 2019. Front Oncol. 2019. PMID: 31179241 Free PMC article.

8

Identification of an immune-related long noncoding RNA signature that predicts prognosis in breast cancer patients.

Li N, Li Z, Li X, Chen B, Sun H, Zhao K. Li N, et al. Among authors: li z, li x. Biomark Med. 2021 Feb;15(3):167-180. doi: 10.2217/bmm-2020-0268. Epub 2021 Jan 26. Biomark Med. 2021. PMID: 33496624

9

High CTC-TRPC5 Expression Significantly Associated With Poor Prognosis in Radical Resected Colorectal Cancer Patients.

Cai D, Li N, Jin L, Qi X, Hua D, Wang T. Cai D, et al. Among authors: li n. Front Mol Biosci. 2021 Aug 4;8:727864. doi: 10.3389/fmolb.2021.727864. eCollection 2021. Front Mol Biosci. 2021. PMID: 34422911 Free PMC article.

10

Cost-effectiveness analysis of elacestrant versus standard endocrine therapy for second-/third-line treatment of patients with HR+/HER2- advanced or metastatic breast cancer: a US payer perspective.

Zeng W, Cao X, Lin J, Zheng B, Li N, Liu M, Cai H. Zeng W, et al. Among authors: li n. Front Oncol. 2023 Dec 19;13:1272586. doi: 10.3389/fonc.2023.1272586. eCollection 2023. Front Oncol. 2023. PMID: 38169749 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26,163 results

Search Page

Filters